Should you buy this growth stock after its 16% surge in revenue?

Is this company ripe for investment after a positive update?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Rentokil (LSE: RTO) has reported an upbeat story for the third quarter of the year. It shows that the pest control and support services company is making good progress in growing its top and bottom lines. However, does it represent a sound investment opportunity for the long term?

Rentokil’s revenue from ongoing operations increased by 16.6% in the third quarter. Of this figure, 3.1% was organic and 13.5% was from acquisitions. Its pest control division delivered an excellent performance and was able to grow organically by 5.9%. Similarly, Rentokil’s hygiene business demonstrated further improvement and grew organically by 3.2%.

As has been the case in recent periods, Rentokil’s performance in emerging and growth markets was particularly strong. Its sales rose by 20.4% in the former and by 26.3% in the latter. This helped to offset a somewhat challenging performance in parts of Europe, with France in particular proving to be a tough market.

During the quarter, Rentokil acquired 13 businesses which included 10 in pest control. All of the acquisitions were in emerging or growth markets and this provides Rentokil with a sound long term growth platform, since demand for support services is likely to increase rapidly in those markets.

Looking ahead, Rentokil is forecast to increase its bottom line by 25% in the current year and by a further 12% next year. Combined with a price-to-earnings (P/E) ratio of 22.5, this puts it on a price-to-earnings growth (PEG) ratio of 1.9. This represents a fair value for the company, given its long-term growth potential in emerging markets.

Furthermore, Rentokil has impressive income potential. It yields only 1.4% at the present time, but pays out less than a third of profit as a dividend. With such strong profit growth potential over the medium-to-long term, Rentokil’s dividends could rise at a rapid rate and could even be ahead of earnings growth in future years. Combined with its diverse business operations and geographical diversity, this makes Rentokil a sound purchase.

Upside potential

However, within the support services space there’s better value for money and higher yields available. For example, G4S (LSE: GFS) is forecast to grow its earnings by 4% this year and by 12% next year. When combined with a P/E ratio of 15.3, this puts it on a PEG ratio of 1.3. While Rentokil is fair value for money, G4S offers significantly greater upside potential over the medium term.

Similarly, G4S has a higher yield than Rentokil. It currently yields 4.1% and while dividends are not as well covered at 1.6 times versus 3.1 for Rentokil, G4S has sufficient headroom to make its dividend outlook relatively secure. Its strong profit growth outlook also means that dividends could grow at a brisk pace.

While both stocks are worth buying for the long term, G4S seems to be the superior buy due to its higher yield and lower valuation.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »